CDC has received reports that some STD programs are currently unable to procure enough penicillin G benzathine (Bicillin L-A®) – the first-line recommended treatment for syphilis – to treat syphilis cases in their jurisdictions. The manufacturer anticipates the issue will be resolved in the next two months. In the meantime, they are working closely with CDC and FDA to address urgent requests. More info...
